(Reuters) -British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that alleged Pfizer's respiratory syncytial virus (RSV) vaccine Abrysvo violated GSK's patent ...

GSK has secured the first regulatory approval for Blenrep since the antibody-drug conjugate’s global market withdrawal in 2022. The U.K.’s Medicines and Healthcare products Regulatory Agency ...

April 3 (Reuters) - British pharmaceutical giant GlaxoSmithKline (GSK.L), opens new tab and rival Pfizer (PFE.N), opens new tab have agreed to end a lawsuit that alleged Pfizer's respiratory ...

And GSK’s first-to-market Arexvy lived up to that expectation with $1.5 billion sales in its first year of commercialization. Related As RSV vaccine clash kicks off, GSK sues Pfizer for patent ...

Some Delaware Supreme Court justices signaled they may be skeptical of a bid by GSK Plc, Pfizer Inc. and other drugmakers to overturn a judge who allowed more than 80,000 lawsuits to proceed to ...

Deutsche Bank analyst Emmanuel Papadakis maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The company’s shares opened today at p1 ...

GSK (GSK) said it is “pleased” that the Advisory Committee on Immunization Practices voted in favor of recommending the use of RSV vaccines including GSK’s AREXVY in adults aged 50-59 who ...

You can reach Andrew on Signal at drewqjoseph.45. GSK’s blood cancer drug Blenrep won regulatory approval in the U.K. on Thursday, marking the medicine’s return to the market after it was ...

The global markets entered 2025 in the hope that the bullish run of the fourth quarter will continue in the first quarter of 2025. However, the uncertainty due to the tariffs led to the reversal ...

Big pharmaceutical companies have been making deals for technologies that could help them get their molecules through this protective membrane and now GSK is joining in, striking up an alliance ...

(Reuters) -British pharmaceutical giant GlaxoSmithKline (NYSE:GSK) and rival Pfizer (NYSE:PFE) have agreed to end a lawsuit that alleged Pfizer’s respiratory syncytial virus (RSV) vaccine ...